Xbrane Acquires Italian Company Primm Pharma, specialists in Slow Release Generics

Stockholm, Sweden – October 14th, 2015 – Xbrane, a commercial phase Biopharmaceutical company specialized in High Demand Complex Generics, expands its operations within the field of biogenerics trough the acquisition of Italian based Primm Pharma with the goal of Introducing the world’s first slow release injectable biogeneric. 

Primm Pharma is specialized in the development and production of pharmaceutical formulations for slow release injections and has a portfolio currently consisting of five slow release biogeneric candidates. The lead product Spherotide will primarily be used for the treatment of prostate cancer and endometriosis and will be available in emerging markets from mid 2017.

“Through the acquisition of Primm Pharma we are able to broaden our expertise within the field of High Demand Complex Generics. Primm Pharma has unique expertise in microsphere-based drugs and a lead product Spherotide that we believe will become the world’s first slow-release biogeneric for a sizable prostate cancer drug, commented Martin Åmark, CEO of Xbrane.

The Primm Pharma acquisition extends Xbrane’s current portfolio to 8 development candidates. It reflects the company’s mission to bring affordable biogeneric versions of the latest biological drugs to patients suffering from critical diseases in underserved markets. Xbrane estimates the initial value of this market for its portfolio alone to be around USD10 billion and, as a first step, earlier this month signed an agreement with Pooyesh Darou for the introduction of Spherotide into the Iranian market.

 

About Xbrane 

Xbrane is a commercial phase Swedish Biopharmaceutical Company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing biogenerics for injectable slow release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company’s portfolio of High Demand Complex Generics.

Xbranes’s headquarters is located in Stockholm and the company’s in-house research and development facilities are in Sweden and Italy.

 

For further information, please contact:

Martin Åmark, CEO, Xbrane

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

 

Siavash Bashiri, COO, Xbrane

M: +46 (0) 734-343 619

E: siavash.bashiri@xbrane.com

 

www.xbrane.com